| Oct 2 |
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
|
| Oct 1 |
Gilead Sciences (GILD) Increases Despite Market Slip: Here's What You Need to Know
|
| Oct 1 |
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
|
| Oct 1 |
Gilead Sciences: My Worst Stock Move In 2024, And What I Learned From It
|
| Sep 25 |
FTC weighs in on reverse-payment generic delay case involving Gilead, Teva
|
| Sep 25 |
Championing HIV Services for LGBTQ+ Youth
|
| Sep 24 |
Gilead Sciences (GILD) Stock Slides as Market Rises: Facts to Know Before You Trade
|
| Sep 24 |
Top 4 Health Care Stocks That May Keep You Up At Night
|
| Sep 23 |
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
|
| Sep 23 |
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
|
